Case report reveals potential of immunotherapy for recurrent cancers in Lynch Syndrome patients, suggesting individualized management is crucial.
We report a 35-year-old woman with dual malignancies associated with Lynch Syndrome, diagnosed with Stage IIIC sigmoid colon adenocarcinoma and Stage IIA left ovarian serous papillary adenocarcinoma. Germline testing revealed MSH2 gene mutation, particularly exon 7 deletion. This case highlights the importance of early detection, germline testing and individualized management strategies for Lynch Syndrome patients. It also underscores the potential of immunotherapy as an effective therapy for recurrent Lynch-associated cancers, emphasizing the need for continuous research into novel therapeutic modalities.
No takes yet. Share an insight, caveat, or question.
Jian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: